-- Peer-reviewed publication reports faster decongestion with Reprieve Therapy and no increased risk of safety events or worsening kidney function compared to optimal diuretic therapy -- Reprieve ...
MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced topline results ...
Hosted on MSN
Reprieve secures $61m for ADHF system trial
Reprieve Cardiovascular has closed an oversubscribed $61m Series B financing round, which was spearheaded by Deerfield Management. The funds aim to accelerate the global FASTR II pivotal trial of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results